Andere Sprachen Exelixis, Inc.

Aktien

936718

US30161Q1040

EXEL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.05.2024			% 5 Tage	% 1. Jan.
21,23 ^USD	+0,52 %		-2,44 %	-11,50 %

14.05.	Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM
14.05.	Transcript : Exelixis, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Exelixis Files Patent Complaint Against Cipla's Cancer Treatment	10.05.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May	07.05.
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	30.04.
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion	30.04.
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M	30.04.
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29	30.04.
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.	30.04.
Exelixis: Q1 Earnings Snapshot	30.04.
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update	30.04.
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024	30.04.
Exelixis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30.04.
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024	16.04.
North American Morning Briefing : Big Banks Kick -2-	12.04.
Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	29.03.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March	27.02.
BioInvent International AB Year-end report January 1, December 31, 2023	23.02.
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	22.02.
BioInvent International AB Year-end report January 1 – December 31, 2023	22.02.
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	06.02.
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Exelixis, Inc.

Aktien

936718

US30161Q1040

EXEL

Andere Sprachen

Filter